临床试验Nct页
Clinical Trial Results:
NATIONAL, MULTICENTER, RANDOMIZED,OPEN STUDY TO EVALUATE EFFICACY AND SAFETY OF LAMIVUDINE (300 MG QD) MONOTHERAPY AS AN ALTERNATIVE TO THERAPEUTIC INTERRUPTION IN PAZIENTS AFFECTED BY HIV-1, IN VIRAL FAILURE, WITH M184V MUTATION.
PREMATURELY ENDED
| Summary | |
EudraCT number | 2004-001590-26 |
Trial protocol | IT |
Global completion date | |
| Paediatric regulatory details | |
Is the trial part of an agreed EMA paediatric investigation plan? | |
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | |
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | |
| Results information | |
Results version number | v1(current) |
This version publication date | 22 Sep 2021 |
First version publication date | 22 Sep 2021 |
Other versions | |
Summary report(s) | MAS QUE NADA_Statement on discontinuation of the study |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03 for further information.